Research Laboratory, IBIMA-Regional University Hospital of Malaga-UMA, M alaga, Spain, 7 Allergy Unit, Regional University Hospital of Malaga-IBIMA-UMA, M alaga, Spain. RATIONALE: Several randomized double-blind placebo-controlled trials have demonstrated the beneficial clinical effect of allergen immunotherapy (AIT) in improving symptoms, medication requirements and quality of life of local allergic rhinitis (LAR) patients. This study intends to investigate two new aspects: 1: the long-term clinical effect of AIT after its discontinuation; 2: the capacity of AIT to prevent asthma onset in LAR patients. METHODS: Objective 1: two-year prospective study of 19 LAR individuals who satisfactorily responded to three-year treatment with grass-AIT. Objective 2: comparative study of the previous individuals (AIT group) and LAR patients not receiving AIT (not-AIT). An assessment of the clinical state, asthma presence, use of rescue medication, visits to the emergency department, quality of life (RQLQ), and a nasal allergen provocation test (NAPT) were performed at baseline (the moment of AIT discontinuation in the treated group) and two years later. RESULTS: Two years after AIT discontinuation, 94.7% of patients in the AIT group maintained a similar/better clinical state, 89.5% showed a similar/lesser consumption of rescue medication, 73.7% reported a similar/ better RQLQ (P>0.05), and there was an increase in the concentration of allergen tolerated in the NAPT. During the study period, 25% of not-AIT patients required visits to emergency department and 11.9% developed asthma, whereas no visit or asthma cases occurred in the AIT group (P<0.001). CONCLUSIONS: Three years of grass-AIT induces a long-term clinical effect on LAR, which persists after therapy discontinuation, and prevents asthma. This effect might be related to the achievement of immunological tolerance. RATIONALE: Pain and swelling are common adverse reactions of allergen subcutaneous immunotherapy (SCIT) and can affect its tolerability in many children METHODS: We conducted a quality improvement project with the use of pain control interventions (BuzzyÒ vibratory device and ice packs) with SCIT. We administered patient/parent surveys to pediatric SCIT patients prior to SCIT to assess for history of pain or swelling with SCIT and the child's current level of coping with SCIT (05coped very poorly, 55 coped very well) and after 30 minutes of SCIT. RESULTS: Fifteen parents/patients completed pre and post-SCIT surveys from June-August 2018. Baseline pre-SCIT surveys revealed a history of pain and swelling with SCIT in 27% (4/15) and 40% (6/15) children, respectively. 80% (12/15) used the offered comfort devices. The 3 patients who declined comfort measures reported tolerating SCIT without pain or swelling. Half (6/12) of patients who received comfort measures had a history of pain or swelling. 75% (9/12) used ice, 17% (2/12) used ice and the vibratory device, and 8% (1/10) used the vibratory device. Comfort measures improved pain and swelling in 92% (11/12) and 100% (12/12), respectively. All (6/6) patients with a history of pain or swelling with SCIT reported improvement with comfort measures. There was significant improvement in parental anxiety with comfort measures (P<0.001). CONCLUSIONS: The majority of pediatric patients tolerate SCIT well. Those with a history of pain or swelling with SCIT had improvement with the use of non-pharmacologic comfort measures. Increasing awareness of comfort measures will improve SCIT tolerability.
